Tuesday, February 24, 2026
Today, Abcuro released topline results from their Phase 2/3 MUSCLE study evaluating ulviprubart in patients with inclusion body myositis (IBM). Briefly, the study did not demonstrate significance against its endpoints. However, a subgroup of patients with mild to moderate disease at baseline did show trends in improvement. This gives us hope that ulviprubart may potentially be able to modify disease progression for those whose disease progress is on the early side.
Read Abcuro’s full announcement.
We know that news like this can stir a mix of emotions—hope, frustration, fatigue, and everything in between. Clinical research is rarely a straight line, and progress in rare diseases often comes in steps that feel smaller than we wish. Still, each study, each data point, and each patient voice moves us forward.
We are grateful to everyone who recently participated in the TMA x Abcuro survey on the IBM diagnostic journey. Your willingness to share your experiences—often difficult, always deeply personal—continues to guide our advocacy, research priorities, and conversations with industry partners.
The MUSCLE study results will be discussed at the Global Conference on Myositis (GCOM) at the end of March. TMA and Myositis Clinical Trials Consortium (MCTC) will host a Research Briefing from GCOM webinar on May 4. Please join us to learn more updates from this and other trials in myositis.
In the meantime, let us not be too discouraged. It is difficult to see sometimes amidst the setbacks, but we know that together we are inching closer and closer to TMA’s vision of a world without myositis.